Terrapin, a national cannabis leader with a medical marijuana processor license in Pennsylvania, is spearheading an effort to modernize Act 16, Pennsylvania’s medical cannabis law.
Today, the company is launching a campaign to prioritize the 400,000 Pennsylvania patients who rely on medical cannabis for a variety of conditions ranging from children suffering from autism and epileptic seizures, seniors with glaucoma and Parkinson’s disease, and countless others who have been diagnosed with cancer, multiple sclerosis (MS) and Huntington’s disease.
When Act 16 was signed into law in April 2016, it established the state’s medical marijuana growing, processing and dispensing industry.
“Anniversaries are a good time to take stock of an industry’s development, understand what we’ve learned, and set a course for where we go from here,” said Chris Woods, CEO of Terrapin. “After five years, we know that Act 16 has improved the quality of life for many Pennsylvanians, but more must be done to meet patient needs.”
Read more at fox56.com